Navigation Links
Chiltern Appoints Jane Turner as Late Phase Director for Europe

LONDON, Feb. 27 /PRNewswire/ -- Chiltern a leading global clinical research organization announced today that it has appointed Ms. Jane Turner to the post of Director, Late Phase, Europe.

Ms. Turner brings over 24 years of experience to her new position in Chiltern's global Late Phase Organization. Ms. Turner previously held executive positions in both CRO and Pharmaceutical companies, enabling her to acquire considerable knowledge of the operational side of management in both industries. In her most recent position, Jane worked on the management of Late Phase studies with focus on a European setting. Jane's operational base will be Chiltern's global headquarters in Slough, United Kingdom. Jane received a B.Pharm from the University of Nottingham and a Diploma in Clinical Science from the University of Wales.

"I am pleased that Jane chose to bring her expertise and experience to Chiltern," said Steve Albrecht, Chiltern's Senior Director, Late Phase (global). "Our global Late Phase Team has grown significantly over the past few years and Jane's extensive business and operational experience will help us bring innovative and high quality solutions to exceed our sponsors varied Late Phase needs," Steve added.

"I am delighted to join Steve and the global Late Phase group at Chiltern," Jane Turner stated. "There is an increasing demand from both the regulatory authorities and the public for Late Phase studies especially in the domain of drug safety. These requests can negatively affect our sponsors with added costs and time delays; therefore it is imperative that CROs continue to look for innovative solutions while preserving the integrity of the data and the safety of the subjects."

"Jane adds significant strength to our global Late Phase Team," commented James Esinhart, Executive Vice President, Biometrics & Late Phase. "We are experiencing increased demand for Chiltern's Late Phase services utilizing our expertise, our global Call Centers and our web-based data collection platforms to provide sponsors with the unique services required for their marketed products. We are looking forward to Jane's keen insights as we customize our services to meet the needs of the key stakeholders, ie, our sponsors, the regulatory authorities, and the patients."

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad therapeutic range for a wide variety of clients. Chiltern has 1,400 employees located in 24 offices throughout Europe, the Americas and Asia. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.

    For More Information Contact:
    Catherine Lemercier                       Richard Baptista
    Chiltern International, Inc.              Chiltern International Ltd.
    2111 Palomar Airport Road                 171 Bath Road
    Suite 200                                 Slough
    Carlsbad                                  Berkshire
    CA 92011                                  SL1 4AA
    USA                                       UNITED KINGDOM
    Tel: 1 (760) 707 5025                     Tel: +44 (0) 1753 512 000
    Fax: 1 (760) 707 5022                     Fax: +44 (0) 1753 511 116
    Email:                                    Email:

SOURCE Chiltern
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chilterns Resourcing Solutions Division Appoints New Managers to Spain and the United Kingdom
2. Chiltern and EPS INTERNATIONAL Enter Into a Global Partnership
3. Chiltern Enhances Its Portfolio of Electronic Data Capture (EDC) Services With the Addition of Hosting and eCRF Design Services for DataLabs (by ClinPhone) and Medidata Rave(R) Certification
4. Chiltern Expands Its Global Reach to Latin America
5. Chiltern Announces New Expansion in Portugal
6. Chiltern Opens a New Office in Russia
7. Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CROs Meeting in Las Vegas, April 14 - 16, 2008.
8. Chiltern Wins Top Prize
9. Chiltern Announced Today That it has Acquired the Business of Drug Development Solutions (DDS)
10. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
11. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
Post Your Comments:
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... in America. As people age, more care is needed, especially with Alzheimer’s, dementia ... medical professionals are being overworked. The forgotten part of this equation: 80 percent ...
(Date:11/27/2015)... ... November 27, 2015 , ... An inventor, ... to dispense prescription medications at home, so he invented the patent-pending ELECTRONIC M.D. ... dispense prescription medications. In doing so, it could help to prevent potential overdose ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Nov. 29, 2015  The GE Health Cloud 1 ... Society of North America (RSNA) meeting ... healthcare industry, the new cloud ecosystem and its applications will ... care pathways and multidisciplinary teams – both inside and outside ... and CEO of GE. "As the digital industrial leader, we ...
(Date:11/27/2015)... 27, 2015 Une nouvelle ... au Bremachlorin contre le cancer avancé.    ... combiner l,immunothérapie au traitement photodynamique au Bremachlorin contre ... Une nouvelle approche consistant à combiner l,immunothérapie ... avancé.    Clinical Cancer Research ...
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
Breaking Medicine Technology: